Market Access News | pharmaphorum

News

FDA turns down MSD, Daiichi Sankyo HER3 ADC for lung cancer

The FDA has said it cannot approve MSD and Daiichi Sankyo’s HER3-targeted antibody-drug conjugate (ADC) patritumab deruxtecan because of problems at a third-party manufacturer.

News

England, Denmark back CSL’s haemophilia B gene therapy

It has been a good week for CSL Behring as it rolls out haemophilia B gene therapy Hemgenix, with positive reimbursement decisions in both the UK and Denmark.

News

Verona’s first-in-class COPD drug ‘could transform market’

Verona Pharma has claimed FDA approval for its chronic obstructive pulmonary disease (COPD) drug ensifentrine, which has been tipped as a future blockbuster.

News

Wales and NI follow England in backing Vertex CF therapies

Three of the four UK nations have agreed a long-term deal with Vertex Pharma for reimbursement of its cystic fibrosis therapies, ensuring permanent access to the drugs for eligible patients

News

Daiichi Sankyo’s Ezharmia cleared in Japan for rare lymphoma

Daiichi Sankyo has a second approval in Japan for Ezharmia, its first-in-class dual EZH1 and EZH2 inhibitor, as a treatment for relapsed or refractory peripheral T-cell lymphoma (PTCL).

News

BMS gets FDA approval for Krazati in colorectal cancer

Bristol-Myers Squibb’s KRAS inhibitor Krazati has been approved for a second indication, colorectal cancer (CRC), which could inject some much-needed sales growth into the product.

FDA turns down MSD, Daiichi Sankyo HER3 ADC for lung cancer

England, Denmark back CSL’s haemophilia B gene therapy

Verona’s first-in-class COPD drug ‘could transform market’

Wales and NI follow England in backing Vertex CF therapies

Daiichi Sankyo’s Ezharmia cleared in Japan for rare lymphoma

BMS gets FDA approval for Krazati in colorectal cancer

Amgen's Imdelltra scores again in small cell lung cancer

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks